Biocon’s board of directors is scheduled to meet on December 06, 2025, to consider and approve proposals including an investment in Biocon Biologics Limited (BBL), an unlisted material subsidiary. This investment may involve purchase or acquisition of securities from BBL shareholders using cash or company equity shares. The board will also consider raising funds through commercial paper, equity shares, or other eligible securities via private placement, qualified institutions placement, rights issue, or public offer.
Investment in Biocon Biologics Limited
The Board of Directors will consider an investment in Biocon Biologics Limited (“BBL”), an unlisted material subsidiary of the Company. This may be achieved through the purchase or acquisition of securities from existing BBL shareholders. Consideration for these securities may be in the form of cash and/or the issuance and allotment of fully paid-up equity shares of Biocon on a preferential allotment basis through private placement.
Fundraising Considerations
The board will also deliberate on raising funds through various methods. These include the issuance of commercial paper via private placement, and/or equity shares or other eligible securities. These instruments may be offered through one or more permissible modes. Potential avenues for fundraising that will be assessed are qualified institutions placement, rights issues, preferential issues, and further public offers, potentially executed in one or more tranches.
Source: BSE